HemaSphere

· 3 papers in corpus
observational 2023
doi:10.1097/hs9.0000000000000867 ·PMID:36999006

Severe thrombocytopenia is a relatively uncommon event in myelodysplastic syndromes (MDS) and may occur in high-risk patients, advocating treatment with hypomethylating agents or with allogeneic bone marrow transplantation.1 In low-risk pat…

rct 2023
doi:10.1097/hs9.0000000000000966 ·PMID:37901848

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients' quality of life. Fatigue is a multifactorial and burdensome MF-related…

other 2022
doi:10.1097/hs9.0000000000000778 ·PMID:36204692

Anemia is a prevalent and burdensome clinical manifestation of myelofibrosis (MF) with a complex etiology. Most MF patients are anemic within 1 year of diagnosis, and nearly all become dependent on red blood cell transfusions over time.1 An…